Hot demand for vaccine doses might start cooling soon.
Compare MRNA Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Moderna Inc.
The vaccine maker announced two promising developments.
It's a tough question to answer. But here's a stab at it.
More blockbusters may be in Moderna's future.
Deutsche Bank initiated coverage on the vaccine stock with a sell rating.
The company's COVID-19 vaccine might have set the stage for something big.
They've risen too far, too quickly.
There's a super-bullish estimate for Moderna's 2022 sales.
The vaccine maker has a promising pipeline but an expensive valuation.
The company's COVID-19 vaccine has been a massive success, but how much is the underlying technology worth?